Tohoku University Technology: HDAC and PI3K inhibitor for cancer treatment: T11-036
low molecular weight compound with anti-cancer activity for nano-molarity
PI3K / AKT pathway is known as the major signaling pathway involved in survival and proliferation of cells. This is also known as the therapeutic target for cancer because this is aberrantly-activated for various cancer cells. Therefore, the inventors screened compounds with PI3K inhibitory activity from hundreds of compound. The results show that FK228 (a.k.a. Istodax(R)), HDAC inhibitor, and its analogs have PI3K inhibitory activity.
Inquire About This Product
basic information
For details, please contact us or refer to the PDF.
Price range
Delivery Time
Applications/Examples of results
For details, please contact us or refer to the PDF.
catalog（1）
Download All Catalogs
Company information
The revenue generated from technology transfer is reinvested as new research funding for universities and researchers, and is utilized to create further research outcomes. To ensure the smooth operation of this cycle, known as the "Intellectual Creation Cycle," we will vigorously promote technology transfer. The types of seeds we handle include patents, know-how, databases, and programs. We have established a collaborative framework by signing basic technology transfer agreements with the following universities (as of June 1, 2025): Tohoku University, Hirosaki University, Iwate University, Akita University, Fukushima University, Yamagata University, Tohoku Gakuin University, Iwate Medical University, Fukushima Medical University, Aizu University, Miyagi University, Hokkaido University, Muroran Institute of Technology, and Showa Medical University.
![[Leveling Correction] Leveling correction of concrete floors "Teratec Method"](https://image.mono.ipros.com/public/product/image/d08/1267539002/IPROS70063422645318547243.jpeg?w=280&h=280)
